Related Experiment Video
Updated: Oct 23, 2025
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
Published on: November 26, 2010
LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells
Takahiro Yamazaki1, Erik Wennerberg1, Michal Hensler2
1Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
Abstract:
LTX-315 is a nonameric oncolytic peptide in early clinical development for the treatment of solid malignancies. Preclinical and clinical evidence indicates that the anticancer properties of LTX-315 originate not only from its ability to selectively kill cancer cells, but also from its capacity to promote tumor-targeting immune responses. Here, we investigated the therapeutic activity and immunological correlates of intratumoral LTX-315 administration in three syngeneic mouse models of breast carcinoma, with a focus on the identification of possible combinatorial partners. We found that breast cancer control by LTX-315 is accompanied by a reconfiguration of the immunological tumor microenvironment that supports the activation of anticancer immunity and can be boosted by radiation therapy. Mechanistically, depletion of natural killer (NK) cells compromised the capacity of LTX-315 to limit local and systemic disease progression in a mouse model of triple-negative breast cancer, and to extend the survival of mice bearing hormone-accelerated, carcinogen-driven endogenous mammary carcinomas. Altogether, our data suggest that LTX-315 controls breast cancer progression by engaging NK cell-dependent immunity.
Insights
LTX-315, an oncolytic peptide, effectively controls breast cancer by activating natural killer (NK) cell immunity. This therapy shows potential for combination with radiation therapy to enhance anti-cancer immune responses.
Area of Science:
- Oncology
- Immunology
- Peptide Therapeutics
Background:
- LTX-315 is an oncolytic peptide with demonstrated anticancer properties.
- Its efficacy is linked to direct cancer cell killing and immune response modulation.
- Investigating LTX-315's role in breast cancer and potential combination therapies is crucial.
Purpose of the Study:
- To evaluate the therapeutic activity of intratumoral LTX-315 in mouse models of breast carcinoma.
- To identify immunological correlates of LTX-315 treatment.
- To explore LTX-315 as a combinatorial partner, particularly with radiation therapy.
Main Methods:
- Utilized three syngeneic mouse models of breast carcinoma.
- Administered LTX-315 intratumorally.
- Assessed therapeutic activity, tumor microenvironment changes, and immune cell involvement (including NK cell depletion).
Main Results:
- LTX-315 treatment led to breast cancer control.
- A reconfiguration of the tumor immunological microenvironment was observed, supporting anticancer immunity.
- Combination with radiation therapy boosted LTX-315's effects.
- Depletion of natural killer (NK) cells impaired LTX-315's efficacy in limiting disease progression and extending survival.
Conclusions:
- LTX-315 controls breast cancer progression through NK cell-dependent immunity.
- The immunological microenvironment modulation by LTX-315 can be enhanced by radiation therapy.
- LTX-315 demonstrates significant therapeutic potential in breast cancer, particularly via immune engagement.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...